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Abstract: Antihypertensive therapy can lower the risk of cardiovascular morbidity and mortality. 
Yet, partly because of inadequate dosing, wrong pharmacological choices, and poor patient 
adherence, hypertension control remains suboptimal in the majority of hypertensive patients. 
Achieving greater blood pressure control requires a multifaceted approach that raises awareness 
of hypertension, uses effective therapies, and improves adherence. Particular classes of anti-
hypertensive therapy have beneficial actions beyond blood pressure and studies have evaluated 
differences in cardiovascular protection among classes. The LIFE and HOPE studies showed 
between-class differences that may be due to effects other than blood pressure-lowering. In the 
ONTARGET study, telmisartan and ramipril provided similar cardiovascular protection but 
adherence was higher with telmisartan, which was better tolerated. This difference in compli-
ance is likely to be important for long-term therapy. The selection of an agent for cardiovascular 
protection should depend on an appreciation of its composite properties, including any beneficial 
effects on tolerability and increased patient adherence, as these are likely to be advantageous for 
the long-term management of hypertension. This review examines the evidence that the effects 
beyond blood pressure provided by some antihypertensive agents can also lower the risk of 
cardiovascular, cerebrovascular, and renal events in patients with hypertension.
Keywords: angiotensin II receptor blocker, cardiovascular continuum, cardiovascular disease, 
hypertension, renin–angiotensin system, telmisartan
Introduction
The incidence of cardiovascular, cerebrovascular, and renal events attributable to 
elevated blood pressure remains high despite the known consequences of uncontrolled 
hypertension and the impressive body of evidence for risk reduction with therapeutic 
intervention. As blood pressure is a major modifiable risk factor, efforts should be 
directed at achieving good blood pressure control at an individual and population level. 
This review considers the reasons for the suboptimal management of hypertension and 
approaches to improving management. An agent that provides effective and sustained 
control of blood pressure must be the central part of any therapeutic approach to 
reducing the risk of cardiovascular, cerebrovascular, and renal events. Large outcome 
trials have angiotensin-converting enzyme (ACE) inhibitors and angiotensin II recep-
tor blockers (ARBs) providing end-organ protection in high-risk patients. There are 
many contributors to cardiovascular risk in addition to hypertension and these trials 
also implicate blood pressure-independent mechanisms in reducing cardiovascular risk, 
suggesting that an agent with these ancillary properties will offer enhanced cardiovas-
cular protection. This review explores this topical theme and examines the evidence Vascular Health and Risk Management 2010:6 480
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that effects beyond blood pressure can also lower the risk of 
cardiovascular, cerebrovascular, and renal events.
Hypertension as a risk factor for cardiovascular  
and cerebrovascular complications
Hypertension is a major risk factor for cardiovascular and 
cerebrovascular morbidity and mortality. The evidence 
from epidemiologic studies and clinical trials has led to 
the consensus that blood pressure needs to be aggressively 
controlled. Blood pressure targets are generally consistent 
among the guidelines produced by national and international 
bodies.1–3 In the Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treatment 
of High Blood Pressure (JNC 7), a blood pressure target 
of 140/90 mmHg is recommended for individuals with 
uncomplicated hypertension (ie, no end-organ damage or 
clinical cardiovascular disease).1 Reflecting higher risk, the 
targets are lower for those with diabetes (130/85 mmHg) 
and for patients with renal insufficiency and proteinuria 
greater than 1 g per 24 h (125/75 mmHg). As in the JNC 
7 guidelines, the blood pressure goal for hypertensive 
patients with no other cardiovascular disease risk factors is 
140/90 mmHg in the American Heart Association (AHA) 
and the European Society of Hypertension (ESH) and of the 
European Society of Cardiology (ESC) recommendations.2,3 
Also, in common with the JNC 7 guidelines, the blood pres-
sure targets are lower in patients with additional risk factors 
for cardiovascular disease.
Nonpharmacologic interventions (eg, body weight reduc-
tion, exercise, salt restriction, and alcohol intake reduction) 
yield heterogeneous results and not all may give clinically 
significant reductions. The most effective approach appears 
to be weight loss, which may lower systolic blood pressure 
by 3–5 mmHg.4,5 Educational measures, such as sessions 
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with health care professionals or provision of materials, are 
unlikely to lead to clinically significant reductions in blood 
pressure.6 Thus, alongside lifestyle interventions, antihyper-
tensive medication is generally required to achieve blood 
pressure goals. Potent and sustained reductions in blood 
pressure, such as those provided by ARBs and ACE inhibitors, 
are a requirement of antihypertensive therapy. However, there 
can be differences in efficacy between classes and even within 
a class. The differences within a class may reflect important 
attributes such as half-life, with a longer half-life providing 
a longer duration of antihypertensive effect. Therefore, it is 
important to consider each agent individually, to compare the 
blood pressure-lowering effects of different agents at effective 
therapeutic doses, and to distinguish between studies that 
have done so and those that have not.7,8
Suboptimal management  
of hypertension
Despite awareness of the consequences of uncontrolled 
hypertension and the impressive body of evidence that blood 
pressure control significantly reduces the risk of cardiovascular, 
cerebrovascular, and renal events, the management of hyper-
tension remains suboptimal. In an analysis of the US National 
Health and Nutrition Examination Survey (NHANES) 
in 1999–2000, hypertension, defined as blood pressure 
140/90 mmHg, was present in 28.7% of the population.9 Of 
those with hypertension, 68.9% were aware of their diagnosis 
but only 58.4% were treated, and control of blood pressure (ie, 
140/90 mmHg) was achieved in only 53.1%. This under-
treatment is apparent worldwide. In Canada, the prevalence 
of hypertension (blood pressure 140/90 mmHg for general 
population; 130/80 mmHg for patients with type 2 diabetes; 
160 mmHg for isolated systolic hypertension) in a large 
primary care database was 17.3%.10 Most patients (68.6%) had 
untreated hypertension; only 15.8% had treated and controlled 
blood pressure. Undertreatment of hypertensive individuals has 
also been reported in Italy,11,12 the UK,13 The Netherlands,14 
Germany,15 and Belgium.16
Approaches to improving  
the management of hypertension
Among the reasons why hypertension may go unrecognized, 
a major contributor is likely to be a lack of appreciation 
among the general population of the importance of blood 
pressure control. Greater awareness in the community of 
the risks of hypertension could contribute to increased con-
sultations for blood pressure measurements and recognition 
of hypertension. Yet, even when public awareness programs 
have been implemented, improvement in the knowledge of the 
importance of blood pressure tends to be short-lived.17 The 
limited duration of their impact is illustrated by a month-long 
media campaign in Canada about the importance of blood 
pressure,17 which increased the number of individuals who 
claimed to have high blood pressure, and also decreased the 
number of patients who were treated and uncontrolled, but 
the changes were not sustained at 6 months. Nevertheless, it 
is incumbent on policymakers and health care professionals 
to initiate a dialogue about the importance of blood pressure 
control.
Undertreatment of hypertension may also arise from 
underprescribing by physicians. This has been attributed 
to lack of awareness of guideline recommendations, the 
difficulty of matching patient preferences with guideline 
recommendations, low motivation and low expectancy of a 
beneficial outcome, physician inertia, and insufficient time 
or resource. Another contributor to patients with hyperten-
sion not reaching treatment goals is lack of adherence to 
prescribed medicines. As high blood pressure does not gener-
ally cause troublesome symptoms, patients’ beliefs about the 
necessity of taking a drug may affect adherence. Similarly, 
side effects experienced when patients initially take medi-
cation may cause them to view the medication unfavorably 
and so decrease their likelihood of taking it in the long term. 
Patients may deliberately not take their medication because 
of concerns over the possibility of side effects, particularly 
if they do not have troublesome symptoms of hyperten-
sion. Some patients may unintentionally forget to take their 
medication, which may be compounded by the complexity 
of the regimen. Compliance with treatment may be further 
affected if the patient is taking a large number of medications; 
a situation that is particularly common in elderly patients. 
Therefore, physicians should be alert to poor adherence and 
seek to improve it by engaging patients, emphasizing the 
benefits of treatment, and making the regimen as simple as 
possible.
Improving adherence  
to antihypertensive therapy
Adherence to a treatment regimen is greater with once-daily 
therapy than with more complex regimens, but once-daily 
treatment requires an agent that provides antihypertensive 
efficacy throughout the 24-h dosing interval. This is espe-
cially important for patients who take their medication early 
in the morning as blood pressure is lowest at night during 
sleep, with a sudden sharp increase in the early morning upon Vascular Health and Risk Management 2010:6 482
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waking (the early morning blood pressure surge [EMBPS]).18 
The significance of this surge in blood pressure is suggested 
by the higher incidence of cardiovascular events during the 
morning than at any other time.19–21 A high EMBPS predis-
poses individuals to target-organ damage,22,23 and cardio- and 
cerebrovascular events.24,25
Even in hypertensive patients receiving and adhering to 
treatment, the goal of achieving blood pressure control can 
be elusive. The use of an agent that provides powerful drug 
pressure reductions should be a first step in treating hyperten-
sion. Increasing the dose of antihypertensive monotherapy 
may control blood pressure in some individuals. However, 
the risk of side effects increases with increasing doses for 
diuretics, β-blockers, and calcium channel blockers. Thus, 
titrating the dose to control blood pressure with these classes 
of agents may come at the cost of reduced tolerability and, 
consequently, adherence. Although ARBs or ACE inhibitors 
appear to have a wider therapeutic window, it is important to 
be cognizant of the side-effect profile of each type of agent 
(eg, the association of cough with ACE inhibitors). As most 
patients with hypertension will require lifelong treatment, it 
is essential that any antihypertensive regimen has minimal 
adverse effects and so does not substantially impact on 
quality of life.
The role of combination therapy  
in achieving hypertension goals
While dose titration of a single agent may normalize blood 
pressure in some individuals, it is likely that combination 
antihypertensive therapy will be required in the majority 
of patients to adequately control blood pressure. In the 
Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial (ALLHAT), the target blood pressure 
(140/90 mmHg) was achieved in 66% of all patients.26 
More than 45% of patients were treated with at least two 
antihypertensive agents. The use of combination therapy was 
also high in the Losartan Intervention for Endpoint (LIFE) 
reduction in hypertension study.27 At the end of the 4-year 
study, 66% of patients who received losartan were on at least 
two drugs, as were 62% of those in the atenolol arm. The Val-
sartan Antihypertensive Long-term Use Evaluation (VALUE) 
study compared valsartan- and amlodipine-based regimens 
for a mean follow up of 4.2 years.28 To attain the rates of 
blood pressure control (ie, 140/90 mmHg) observed in 
the valsartan and amlodipine arms (56% vs 62% of patients, 
respectively), a substantial number of patients in each study 
arm required at least two agents (47.6% vs 40.6%, respec-
tively). Consistent with the evidence from these randomized, 
controlled trials, combination therapy has also been shown 
to be required to bring blood pressure under control in 
population surveys. For example, in a 12-year observational 
investigation (1984–1996) of a cohort of 940 hypertensive 
patients in the Brisighella Heart Study (BHS) in Italy, the 
proportion of patients treated for hypertension rose from 
43.8% to 50.3% in men and 50% to 56.6% in women. The 
rate of blood pressure control more than doubled (7.5% to 
17.4% in men and from 7.3% to 18.5% in women), and was 
attributed to the increased use of combination therapy.12
The evidence from observational studies and clinical tri-
als that combination therapy is often required to normalize 
blood pressure has informed US and European guidelines 
that recommend this therapeutic approach as a first-line 
option.1,3 In principle, the combination of two antihyperten-
sive agents that have different mechanisms of action should 
provide greater antihypertensive efficacy than when each 
component is used individually. However, other advantages 
can also ensue. For example, lower doses of the individual 
components may decrease the likelihood of a side effect, 
while complementary actions may prevent side effects. The 
edema that can accompany calcium channel blocker use 
is ameliorated by concomitant use of an ARB or an ACE 
inhibitor, and the unwanted metabolic effects of diuretics 
can also be offset by combination with an ARB or ACE 
inhibitor. A further consideration is the impact of combina-
tion therapy on adherence; it is possible that a patient will be 
more adherent with a fixed-dose single tablet combination 
rather than a regimen that involves a combination of several 
individual agents.29
The evidence for effects beyond 
blood pressure-lowering
Evidence for the reduction in cardiovascular, cerebrovascu-
lar, and renal events with ARBs and ACE inhibitors comes 
from large-scale outcomes trials (Table 1). Alongside the 
recognition that the reduction in blood pressure is a necessary 
goal, there are indications that agents acting on the renin–
angiotensin system (RAS) have blood pressure-independent 
effects that may contribute to the risk reduction.
Cardiovascular protection: myocardial 
infarction
The Heart Outcomes Prevention Evaluation (HOPE) and 
LIFE studies support the hypothesis that antihypertensive 
agents may have beneficial effects beyond their blood 
pressure-lowering effects. In the former, there was a 20% 
reduction in the relative risk of myocardial infarction with Vascular Health and Risk Management 2010:6 483
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ramipril treatment compared with placebo.30 Ramipril 
reduced blood pressure by 3.3/1.4 mmHg in the HOPE study. 
Extrapolations from the Collins and MacMahon analysis sug-
gest that this reduction in blood pressure would be expected 
to reduce the incidence of myocardial infarction by approxi-
mately 5%.31 It is possible that the high-risk population in 
HOPE may have been at greater risk of a vascular event for 
a given level of blood pressure than the low-risk populations 
in the analysis by Collins and MacMahon. However, the risk 
reduction in the ramipril arm was greater than would have 
been inferred from the relationship between blood pressure 
and risk in the placebo arm. The reduction in vascular events 
in the HOPE study was also greater than would have been 
anticipated from the results of the Systolic Hypertension 
in the Elderly Program (SHEP) study in which there was a 
blood pressure reduction of 10/2 mmHg and a lowering in 
risk of a cardiovascular event by 34%.32 Furthermore, the 
effects of ramipril were considered to be greater than those 
attributable to blood pressure-lowering alone among the 3577 
patients with diabetes in the HOPE study. In these patients, 
the reduction in blood pressure was more modest than in 
the overall population (2.2/1.4 mmHg), but the reduction 
in myocardial infarction (22%) was similar to that in all of 
the patients.33 In comparison, the reduction in blood pres-
sure in the UK Prospective Diabetes Study (UKPDS) was 
10/5 mmHg and was accompanied by a lowering in the risk of 
myocardial infarction by 21%.34 It is plausible, as suggested 
by the authors of the HOPE publication, that the possibility of 
excess overnight hypertension in the placebo group may have 
contributed to the difference. A related explanation is that 
blood pressure measurements taken during the daytime may 
have underestimated the (nocturnal) antihypertensive effect 
of ramipril, which was administered as an evening dose.
In the LIFE study, there was no difference in mean blood 
pressure among the 9193 patients randomized to atenolol 
or losartan during the mean follow-up period of 4.8 years.27 
However, there was a 13% reduction in the primary endpoint 
(stroke, myocardial infarction, or death) among patients 
receiving losartan compared with those allocated to atenolol. 
These findings suggest that the vascular protective effects 
of losartan are not solely due to the blood pressure-lowering 
effect. A counter-argument which has been posited is that 
the reduction in the primary endpoint was mainly driven by 
the excess of strokes in the atenolol group.35 It has also been 
suggested that β-blockers are less effective at preventing 
strokes than other classes of antihypertensives, as indicated 
by comparisons with thiazide diuretics.36 Furthermore, the 
results for patients with left ventricular dysfunction in the 
LIFE study were in line with those that would have been 
expected from the relationship between risk reduction and 
blood pressure-lowering observed in other trials in this 
patient group.37,38
Further evidence of the supplemental effects beyond 
blood pressure is provided by the EURopean trial On reduc-
tion of cardiac events with Perindopril in stable coronary 
Artery disease (EUROPA) study. The reduction in cardio-
vascular events in the EUROPA study was greater than 
expected for the observed reduction in blood pressure.39 
There was a mean reduction in blood pressure of 5/2 mmHg 
with perindopril during the 4.2-year follow-up period, which 
was accompanied by 20% risk reduction versus placebo in 
the primary endpoint of cardiovascular death, myocardial 
infarction, or cardiac arrest. The authors of the report stated 
that “this implies that the specific anti-atherosclerotic effects 
of ACE inhibition should not be neglected”.39 The modest 
differences in blood pressure observed between the active 
treatment (ie, amlodipine plus perindopril) and comparator 
in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood 
Pressure Lowering Arm (ASCOT-BPLA) study may also not 
account for the greater effect of treatment on cardiac event 
rates.40 However, higher high-density lipoprotein cholesterol 
levels in the ACE inhibitor plus calcium channel blocker treat-
ment arm of the ASCOT-BPLA study may have contributed 
to the better coronary heart disease outcomes.
In the VALUE study, there was a blood pressure-lowering 
advantage with amlodipine over valsartan (1.5/1.3 mmHg 
after 1 year).28 Despite this difference, the incidence of 
cardiac morbidity and mortality was not significantly differ-
ent between the two treatment groups (10.6% valsartan vs 
10.4% amlodipine, P = 0.49). There was a 19% higher risk of 
myocardial infarction in the valsartan group compared with 
the amlodipine group.28 This difference was most marked in 
the high-risk coronary population in the study, among whom 
79% of the excess myocardial infarctions occurred during 
the first two years of the study. Subsequently, the differences 
between the two groups were less apparent. This has led to 
the suggestion that recommended blood pressure goals need 
to be achieved rapidly, especially in high-risk individuals, 
to avoid serious vascular events.28 Nevertheless, an editorial 
controversially stated that the increased incidence of myo-
cardial infarction with valsartan in the VALUE trial could 
not be accounted for by the difference in blood pressure 
between treatments and that ARBs “may have harmful as 
well as beneficial effects”.41 The editorial led to several sys-
tematic reviews of randomized clinical trials, three of which 
found that treatment with ARBs was not associated with a Vascular Health and Risk Management 2010:6 486
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significantly increased risk of myocardial infarction.42–44 
The view of other authors is that ARBs may have a neutral 
effect on the risk of myocardial infarction45 or may increase 
the risk.46 The Blood Pressure Lowering Treatment Trialists’ 
Collaboration (BPLTTC) analyzed 26 clinical trials and 
concluded that there was no convincing effect of an adverse 
effect of ARBs on any major cardiovascular outcome.47 
Recently, the UMPIRE study demonstrated that ARBs offer 
similar reductions in acute coronary syndrome hospitaliza-
tion to ACE inhibitors (adjusted relative risk [RR] 0.89; 95% 
confidence interval [CI]: 0.76–1.04), and comparable rates 
of myocardial infarction, one of the secondary analyses (RR 
0.84; 95% CI: 0.71–1.01).48 The ONgoing Telmisartan Alone 
and in combination with Ramipril Global Endpoint Trial 
(ONTARGET™), which was conducted in 25,620 patients at 
high risk for vascular events, provides definitive evidence that 
the risk of myocardial infarction does not differ with ARB 
or ACE inhibitor treatment.49 The risk ratio of myocardial 
infarction for telmisartan, the ARB, compared with ramipril 
was 1.07 (95% CI: 0.94–1.22) in this broad-spectrum, high-
risk population.
Cardiovascular protection: heart failure
There was a trend for fewer admissions for heart failure with 
valsartan than among patients receiving the amlodipine-based 
regimen in the VALUE study.28 Although the difference was 
not significant, it is consistent with a meta-analysis which 
found that antihypertensive agents that block the RAS appear 
to be associated with a reduction in heart failure compared 
with other drugs, including calcium channel blockers.50 
Heart failure occurred more frequently with amlodipine than 
with lisinopril (6-year rate: 10.2% vs 7.7%) in the ALLHAT 
study.26 However, this may have been partly attributable to 
the misdiagnosis of peripheral edema in the amlodipine 
group as heart failure. It has been speculated that the dif-
ference between the two drug classes may arise from exces-
sive sympathetic activation observed with calcium channel 
blockers or that the reduction in sympathetic activation noted 
with ARBs51 may have a beneficial effect. Additionally, the 
potential cardioprotective effects of ARBs could theoretically 
contribute to this difference.
Whether or not there are differences between active 
regimens on heart failure has been investigated further in 
prospectively designed overviews of randomized trials by 
the BPLTTC. In one of the earliest analyses, regimens based 
on ACE inhibitors, diuretics, or β-blockers were found to be 
more effective at preventing heart failure than those based on 
calcium channel blockers.52 In a subsequent analysis, ARBs 
appeared to afford greater protection against heart failure 
in patients with diabetes compared with patients without 
diabetes; this difference was not apparent for other classes.53 
In its latest analysis, the BPLTTC found that ARBs and ACE 
inhibitors gave similar reductions in heart failure risk, and 
neither class had an effect on heart failure beyond that attrib-
utable to blood pressure-lowering.47 The Irbesartan in Heart 
Failure with Preserved Systolic Function (I-PRESERVE) 
trial that was conducted in patients with heart failure with a 
preserved left ventricular ejection fraction (45%) showed 
that irbesartan did not improve any of the pre-specified 
outcomes, including the primary composite outcome of 
death from any cause or hospitalization for cardiovascular 
disease (heart failure, myocardial infarction, unstable angina, 
arrhythmia, or stroke).54
Cardiovascular protection: atrial 
fibrillation
Inhibition of the RAS with either ARBs or ACE inhibitors 
has been shown to prevent new onset and recurrence of atrial 
fibrillation in different patient populations. Among patients 
without previous atrial fibrillation, losartan reduced the 
incidence of new onset atrial fibrillation in the LIFE study.55 
In hypertensive patients requiring antiarrhythmic therapy, 
irbesartan in association with amiodarone was found to 
reduce the recurrence of atrial fibrillation.56 In our study, we 
found that telmisartan decreased the incidence of recurrence 
of atrial fibrillation in hypertensive patients not requiring 
antiarrhythmic therapy compared with carvedilol.57 Atrial 
fibrillation was reported in 14.2% (10/70) of patients in the 
telmisartan group compared with 37% (23/62) of those in the 
carvedilol group (P  0.003). Furthermore, the recurrence 
of atrial fibrillation was delayed in the telmisartan group 
compared with the carvedilol group. Recent evidence from 
the Atrial fibrillation Clopidogrel Trial with Irbesartan for 
prevention of Vascular Events (ACTIVE-I), which investi-
gated patients with atrial fibrillation and at least one other 
risk factor, showed no advantage for the primary outcome 
of cardiovascular death, stroke, or myocardial infarction.58 
However, irbesartan did reduce hospitalizations due to heart 
failure by 14% (P = 0.018), a common complication of atrial 
fibrillation.58
The RAS can facilitate the onset and recurrence of atrial 
fibrillation by increasing blood pressure and intracavitary 
atrial pressure and though arrhythmogenic atrial remodeling. 
Both ARBs and ACE inhibitors may prevent atrial fibrillation 
through lowering end-diastolic left ventricular pressure and 
subsequently left atrial pressure, thereby decreasing atrial Vascular Health and Risk Management 2010:6 487
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stretch and dilatation. Experimental models have shown that 
blockade of the RAS may attenuate atrial functional remodel-
ing that disposes to atrial fibrillation.
There is initial evidence that some of the protective 
effect of these agents is due to actions on pathophysiological 
mechanisms other than elevated blood pressure. In trials with 
blockers of the RAS, such as TRACE59 and a sub-study from 
SOLVD,60 there was no placebo control and it is not possible 
to determine whether the effect on atrial fibrillation is the 
result of the blood pressure reduction per se or if the effect is 
specific to blocking of the RAS. However, in the LIFE trial, 
atenolol and losartan had similar blood pressure-lowering 
capabilities, suggesting that antihypertensive efficacy is not 
the whole issue with respect to differences seen in new-onset 
atrial fibrillation.55 The difference between telmisartan and 
carvedilol on atrial fibrillation that we have reported was not 
related to change in blood pressure, left atrial size, and left 
ventricular hypertrophy.57
Apart from blood pressure reduction, there are other 
potential mechanisms by which inhibition of the RAS may 
reduce atrial fibrillation. Atrial fibrillation produces sig-
nificant changes in atrial tissue and the interstitial matrix, 
increasing the amount of fibrous tissue and collagen accu-
mulation.61 These tissue changes can provide a substrate that 
increases the likelihood of atrial fibrillation recurrence. One 
mediator responsible for these changes is angiotensin II.62 
ARBs have been shown to inhibit collagen type I synthesis 
and cause regression of myocardial fibrosis and to reduce 
collagen deposition in the atria. The reduction in the amount 
of fibrous tissue may limit heterogeneity and delay in atrial 
activation.
Another mechanism through which blockade of the RAS 
may affect atrial fibrillation is due to anti-inflammatory 
effects. In addition, the RAS can also facilitate coronary 
atherosclerosis, increase reactive oxygen species, and induce 
atrial fibrosis. It is also possible that the elevation of atrial 
pressure might cause electrical remodeling by upregulation of 
atrial angiotensin type 1 (AT1) receptor expression.63 Block-
ade of local angiotensin II by ACE inhibitors and ARBs could 
attenuate atrial fibrillation-induced electrical remodeling, 
probably by preventing calcium overload. Genetic variation 
in the RAS is also seen to be associated with atrial fibrillation, 
providing further evidence of the important role of RAS and 
the possibly beneficial effect of RAS blockade.
Cerebrovascular protection
In the HOPE study, there was 32% reduction in the 
relative risk of stroke with ramipril treatment compared 
with placebo.30 Extrapolations from the Collins and Mac-
Mahon analysis suggest that the reduction in blood pressure 
achieved in the study would be expected to reduce the inci-
dence of stroke by approximately 13%.31 Furthermore, these 
beyond blood pressure-lowering effects of ramipril were also 
observed in the patients with diabetes in the HOPE study, 
who had more modest reductions in blood pressure than in 
the overall population (2.2/1.4 mmHg), but the reduction in 
stroke (33%) was similar to that in all of the patients.33 Fur-
ther support comes from the UKPDS, which showed that a 
blood pressure reduction of 10/5 mmHg was accompanied by 
a lowering of the risk of stroke by 44%.34 In the LIFE study, 
there was no difference in mean blood pressure among the 
9193 patients randomized to atenolol or losartan during the 
mean follow-up period of 4.8 years.27 However, there was a 
25% reduction in the risk of stroke among patients receiving 
losartan compared with those allocated to atenolol.27 These 
findings suggest that the cerebrovascular protective effects 
of losartan are not solely due to the blood pressure-lowering 
effect, but as previously discussed, alternate explanations 
for the 13% reduction in the primary endpoint (stroke, 
myocardial infarction, or death) and the risk of stroke have 
been posited.35,36
ARBs and ACE inhibitors appear to improve cardiovas-
cular outcomes in comparison with other agents, but in both 
the ALLHAT and VALUE studies, the incidence of stroke was 
lower in the amlodipine treatment arms than in the lisinopril 
and valsartan arms, respectively.26,28 Stroke is a complication 
of hypertension that has a direct relationship with the level of 
blood pressure.64 A 10 mmHg increase in systolic or 5 mmHg 
increase in diastolic hypertension increases the risk of stroke 
by 30% and 20%, respectively.65 A seminal analysis by Col-
lins and MacMahon documented that a 5–6 mmHg reduc-
tion in blood pressure maintained over 5 years reduces the 
incidence of stroke by approximately 40%.31 Subsequent to 
the work by Collins and MacMahon, meta-analyses of large-
scale, active-controlled studies have indicated that lowering 
blood pressure reduces the risk of a cerebrovascular event.52,66 
Thus, small differences in the level of blood pressure control 
may explain some of the differences in the incidence of stroke 
observed between calcium channel blockers and ARBs or 
ACE inhibitors. This difference is likely to be attributable to 
the greatest reductions in blood pressure (eg, the difference 
in systolic blood pressure was 1.2 mmHg at 5 years in ALL-
HAT; 1.5/1.3 mmHg difference after 1 year in VALUE).26,28 
This emphasizes the importance of effective and aggressive 
blood pressure control. Yet there may be differences between 
agents in their effects on stroke that are specific to particular Vascular Health and Risk Management 2010:6 488
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classes. In an overview by the BPLTTC, there was a greater 
effect of calcium channel blocker-based regimens on stroke 
compared with regimens based on diuretics or β-blockers, 
but the result was of borderline significance.52 There was 
also a trend towards greater reductions in stroke risk with 
regimens based on calcium channel blockers and diuretics 
or β-blockers than with regimens based on ACE inhibitors. 
In another analysis, by Verdecchia and colleagues, calcium 
channel blockers appeared to be more effective than ACE 
inhibitors for the prevention of stroke.66
Renal protection
RAS inhibition with either ARBs or ACE inhibitors has been 
shown to reduce proteinuria and end-stage renal disease 
(ESRD). In the IRbesartan in patients with type 2 diabetes 
and MicroAlbuminuria (IRMA2) study, which investigated 
whether or not an ARB (added to a background of other 
hypertensive agents) could delay or prevent the develop-
ment of diabetic nephropathy in hypertensive patients with 
type 2 diabetes and persistent microalbuminuria, 14.9%, 
9.7%, and 5.2% of the placebo, irbesartan 150 mg, and 
irbesartan 300 mg groups, respectively, reached the pri-
mary endpoint of a urinary albumin excretion rate (UAER) 
200 µg/min and 30% higher than the baseline value.67 
In this study, persistent microalbuminuria was defined as 
a UAER of 20–200 µg/min in two of three consecutive 
overnight urine samples. Normoalbuminuria was also more 
frequently restored in patients receiving irbesartan 300 mg. 
As there were no significant differences in the blood pres-
sure-lowering effects between the three groups, the authors 
concluded that the beneficial effects of the ARB appeared 
to be independent of blood pressure-lowering.67 A sub-study 
measuring 24-hour ambulatory blood pressure in 43 patients 
confirmed these findings.68
In the Reduction of Endpoints in Non-insulin-dependent 
diabetes mellitus with the Angiotensin II Antagonist Losar-
tan (RENAAL) study, double-blind losartan 50–100 mg 
in addition to conventional antihypertensive therapy was 
associated with a significant 16% (P = 0.02) risk reduc-
tion versus placebo in the composite primary endpoint of a 
doubling of serum creatinine, ESRD, or death over a mean 
treatment period of 3.4 years.69 The risk reduction was due 
to losartan reducing the incidence of the doubling of serum 
creatinine and ESRD, rather than reductions in mortality. 
The beneficial effect of losartan on the renal endpoints was 
considered to be greater than that due to blood pressure 
reductions alone.
The Irbesartan in Diabetic Nephropathy (IDNT) study 
directly compared irbesartan with the calcium channel 
blocker amlopidine in type 2 diabetes patients receiving addi-
tional antihypertensive drugs to achieve the target SBP/DBP 
of 135/85 mmHg.70 The composite primary endpoint was a 
doubling of serum creatinine, ESRD, or death.70 Irbesartan 
significantly reduced the risk of the primary endpoint by 
20% and 23% (P = 0.02; P = 0.006) compared with placebo 
and amlodipine, respectively, over the mean follow-up of 
2.6 years.70 The authors concluded that the protection against 
nephropathy provided by irbesartan was independent of its 
blood pressure-lowering effects.
The Diabetics Exposed to Telmisartan And enalaprIL 
(DETAIL) study was a head-to-head comparison of an ACE 
inhibitor and an ARB in patients with type 2 diabetes with 
early nephropathy who received either telmisartan or enala-
pril for up to five years.71 Under pre-specified conditions 
(seated DBP was 100 mmHg or SBP was 160 mmHg) 
additional antihypertensive therapy was permitted after two 
months of double-blind treatment. The primary endpoint 
was the change in glomerular filtration rate from baseline. 
Based on the primary outcome, the study demonstrated the 
noninferiority of telmisartan compared with enalapril.71 
The findings of the DETAIL study supported the clinical 
equivalence of ARBs and ACE inhibitors for long-term 
renal protection in patients with type 2 diabetes and early 
nephropathy.
In the telMisartan versus losArtan in hypertensive 
type 2 DiabEtic patients with Overt nephropathy (AMADEO) 
study, a head-to-head comparison of two ARBs, despite 
similar blood pressure reductions after 52 weeks of treat-
ment, telmisartan was associated with significantly greater 
reductions in the primary endpoint (the difference in the 
urinary protein-to-creatinine ratio) compared with losartan 
(P = 0.03).72
Cardiovascular protection: broad  
high risk population
ONTARGET™ is the largest outcome study ever performed 
with an ARB, and the only one to demonstrate protective effi-
cacy in a broad cross-section of patients at high risk of vascu-
lar events (ie, with atherothrombotic cardiovascular disease, 
or type 2 diabetes with target-organ damage).49 It compared 
telmisartan monotherapy with ramipril monotherapy as well 
as comparing the combination of telmisartan and ramipril 
with ramipril monotherapy. Patients were either nonhyperten-
sive or had controlled hypertension at baseline, and received Vascular Health and Risk Management 2010:6 489
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concomitant antihypertensives as needed, ensuring that blood 
pressure differences did not influence the results. There was 
no difference in primary outcome (a composite of cardio-
vascular mortality, nonfatal myocardial infarction, nonfatal 
stroke, and hospitalization for chronic heart failure) between 
telmisartan and ramipril (occurring in 1423 patients [16.7%] 
and 1412 patients [16.5%], respectively).49 Telmisartan was 
better tolerated and associated with a higher compliance rate 
than ramipril over the course of the 56-week study.
The effect of telmisartan on cardiovascular morbidity 
in patients intolerant of ACE inhibitors was evaluated in 
TRANSCEND®.73 As in ONTARGET, patients were at high 
risk of vascular disease, but in TRANSCEND the compara-
tor was placebo on a background of best standard of care.73 
There was no significant difference in the primary outcome 
(which included hospitalizations for heart failure) between 
the study arms, but telmisartan significantly lowered the 
risk of the HOPE study outcome (ie, a composite of cardio-
vascular death, myocardial infarction, or stroke) by 13%.73 
This reduction occurred against a background of non-ARB/
ACEI therapy that was significantly more intensive than in 
the HOPE trial, and which meant that the event rate in the 
placebo arm was relatively low. Remarkably, adherence was 
better with telmisartan than for patients on best standard of 
care, which may be a consequence of higher concomitant 
medication use in the placebo arm.
Confounding factors to consider  
when comparing studies
An important caveat when comparing outcomes from the 
studies discussed above is that patient populations may be 
subtly or markedly different, depending on each study’s 
inclusion and exclusion criteria (Table 1). The influence of 
patient population characteristics is illustrated by a systematic 
review by Dagenais and colleagues of three large outcome 
studies (HOPE, EUROPA, and Prevention of Events with 
Angiotensin-Converting Enyzme inhibition [PEACE]).74 
The analysis evaluated the effect of ACE inhibition on 
cardiovascular outcomes and mortality in patients who had 
stable vascular disease without left ventricular systolic 
dysfunction. ACE inhibition reduced all-cause mortality 
(7.8% vs 8.9%, P = 0.0004), cardiovascular mortality (4.3% 
vs 5.2%, P = 0.0002), all stroke (2.2% vs 2.8%, P = 0.0004), 
and other endpoints such as nonfatal myocardial infarction, 
heart failure, and coronary-artery bypass surgery. There was 
a relative 18% risk reduction in the composite endpoint of 
cardiovascular mortality, nonfatal myocardial infarction, and 
stroke for patients receiving an ACE inhibitor compared with 
those allocated to placebo. A subsequent systematic review 
also reported that ACE inhibitors reduce total mortality and 
major cardiovascular endpoints, including stroke, in patients 
who have coronary artery disease and no heart failure or left 
ventricular systolic dysfunction.75
In the publication by Dagenais, analyses were also per-
formed on data from five long-term studies in patients who 
had heart failure or left ventricular systolic dysfunction.74 
The outcomes in the patients with stable vascular disease 
were generally similar to those in patients with heart failure 
or left ventricular systolic dysfunction. For example, the 
relative 18% risk reduction in the composite endpoint of 
cardiovascular mortality, nonfatal myocardial infarction, 
and stroke was similar to the 21% determined in the higher-
risk patient group. However, although the analysis of the 
HOPE, EUROPA, and PEACE studies showed a clear benefit 
of ACE inhibition on stroke, this effect was not apparent 
among patients with heart failure or left ventricular systolic 
dysfunction. It was suggested that this finding may be due 
to the lower initial blood pressure of patients in these trials, 
the low degree of blood pressure-lowering among them, and 
the relatively low event rates.
The VALsartan In Diastolic Dysfunction (VALIDD) trial 
further illustrates the importance of the characteristics of 
the patient population and confounding factors.76 The study 
was based on the premise that ARBs reduce left ventricular 
hypertrophy and myocardial fibrosis. Patients with diastolic 
dysfunction were randomized to either valsartan or placebo 
for 38 weeks. In addition, they received add-on therapy that 
did not act on the RAS to reach targets of 135/85 mmHg. 
There were no significant differences in measures of 
changes in diastolic function between the two treatment 
groups. This indicates that blood pressure-lowering alone 
was responsible for the improvements in diastolic function. 
An accompanying commentary cautioned that the results 
should be interpreted in the context of the design of the 
study and of the patient population.77 The prevalence of left 
ventricular hypertrophy, and thus of myocardial fibrosis, in 
the study population was low. In addition, the effect of the 
ARB on sympathetic activation may have been ameliorated 
in the third of the population that was taking concomitant 
β-blockers. The authors of the commentary did not exclude 
the potential benefits of valsartan in the population and 
recommended larger trials with longer-term follow-up to 
test whether ARBs improve cardiac function independently 
of blood pressure control.Vascular Health and Risk Management 2010:6 490
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Summary
It is not certain to what extent effects beyond blood pressure 
influence cardiovascular, cerebrovascular, and renal out-
comes. The accumulated evidence from the clinical studies 
outlined above suggests, but does not prove, that ACE inhibi-
tors and ARBs provide greater reductions in these outcomes 
than can be attributed to blood pressure-lowering alone. The 
overall conclusion of the BPLTTC from its analyses is that 
blood pressure reduction has a central role in producing 
the benefits observed.53 Moreover, it concluded that there 
was evidence that ACE inhibitors but not ARBs had blood 
pressure-independent effects on the risk of major coronary 
events.47 However, they did not exclude an effect of ARBs 
on macrovascular risk.
The comparisons between studies from which these infer-
ences are drawn are limited by differences in design, study 
populations, and baseline blood pressures. These differences 
confound the ability to differentiate blood pressure-dependent 
effects from those that are due to effects beyond blood pres-
sure reduction. Nevertheless, the evidence suggests that there 
are differences due to effects beyond those attributable to 
blood pressure reduction alone.
Clinical effects of the combination 
of an ARB and ACE inhibitor
ACE inhibitors and ARBs have mechanistically distinct 
actions that have been hypothesized to have clinically 
relevant consequences. The AT1 receptor mediates several 
pathophysiological effects.78 Interrupting its vasocon-
strictive and osmoregulatory effects contributes to the 
antihypertensive effects of ARBs and ACE inhibitors. The 
AT1 receptor is also associated with endothelial dysfunc-
tion through lipid peroxidation, free radical production, 
smooth muscle and extracellular matrix proliferation, and 
expression of proinflammatory genes (eg, chemoattractant 
proteins, leukocyte adhesion molecules, adhesion, and 
cytokines).79–82
ACE inhibition prevents the degradation of bradykinin 
and the accumulation of bradykinin has been implicated in 
the beneficial cardiovascular effects of ACE inhibitors.83–89 
However, the increase in levels of bradykinin may not be 
totally advantageous as it has been linked to the increased 
incidence of cough seen with ACE inhibitors, although 
other mechanisms are also likely to be involved in ACE 
inhibitor-induced cough.90 Another potential issue with ACE 
inhibitors is that high or maximally recommended doses of 
ACE inhibitors do not completely prevent angiotensin II 
formation,91,92 which suggests the involvement of alternative 
mechanisms (eg, tissue chymases) for converting angioten-
sin I to angiotensin II.
ARBs prevent the activation of the AT1 receptor but, in 
contrast to ACE inhibitors, they do not prevent the potentially 
beneficial effects of modulation of the angiotensin type 2 
(AT2) receptor by angiotensin II.78 The function of the AT2 
receptor is less well understood than that of the AT1 receptor, 
but some of its actions oppose those of the AT1 receptor and 
it has been hypothesized that these actions contribute to the 
vascular protective effects of ARBs.
The prospect of more complete RAS blockade that can 
be provided by a combination of an ARB and an ACE inhibi-
tor is the basis for the suggestion that the combination may 
provide greater cardiovascular protection than the component 
monotherapies. In a meta-analysis of randomized, controlled 
trials, the combination of an ARB and an ACE inhibitor 
reduced ambulatory blood pressure by 4.7/3.0 mmHg com-
pared with ACE inhibitor monotherapy and by 3.8/2.9 mmHg 
compared with ARB monotherapy.93 However, the majority 
of these studies used submaximal doses or once-daily dos-
ing of shorter-acting ACE inhibitors; when a larger dose of 
shorter-acting ACE inhibitor or a longer-acting ACE inhibitor 
was used, there was generally no additive effect of the ARB 
on blood pressure. Additionally, the number of patients on 
combination therapy was small (10–99 patients), the studies 
were relatively short-term (12 weeks), and only three trials 
had uncomplicated hypertension as an entry criterion.
There is some evidence from small-scale studies that a 
combination of an ARB and an ACE inhibitor beneficially 
affects markers of cardiovascular risk.94–96 Large outcome 
studies have investigated the effects of dual RAS control on 
cardiovascular endpoints but the general applicability of these 
findings is limited because they have been performed in dif-
ferent populations and considered different endpoints.37,97,98 
In the Candesartan in Heart failure: Assessment of Reduction 
in Mortality and morbidity (CHARM)-Added Trial, patients 
with New York Heart Association (NYHA) II–IV congestive 
heart failure and left ventricular ejection fraction 40% 
were randomized to ACE inhibitor therapy and additional 
candesartan or placebo.98 Over a median follow-up period of 
41 months, candesartan significantly reduced the number of 
patients who experienced the composite primary outcome 
of cardiovascular death or hospitalization for chronic heart 
failure compared with placebo (38% vs 42%, respectively). 
The Valsartan HEart Failure Trial (Val-HEFT) also found 
that ARB and ACE inhibitor combination therapy improves 
outcomes.97 In contrast, the VALsartan In Acute myocardial Vascular Health and Risk Management 2010:6 491
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iNfarction Trial (VALIANT) found that all-cause mortality 
was similar among its three treatment arms (valsartan, 
captopril, or the combination) over the median 24.7-month 
follow-up period in patients with left ventricular dysfunction 
or heart failure after myocardial infarction.37 In ONTARGET, 
combination therapy with telmisartan and ramipril provided 
no additional benefit to ramipril monotherapy (ie, the primary 
endpoint occurred in 1386 [16.3%] combination-treated 
patients) and was associated with a higher incidence of 
adverse events than ramipril.49 The ESH recently reappraised 
the 2007 ESH/ESC guidelines,3 and in light of the ONTAR-
GET™ findings, warned against the use of ARBs combined 
with ACE inhibitors, at least in patients with very high car-
diovascular risk, such as those in ONTARGET™.99
Conclusion
There is overwhelming evidence that hypertension increases 
the risk of cardiovascular complications and that control of 
blood pressure reduces this risk. Yet, despite some improve-
ments in hypertension awareness and management, control of 
hypertension remains suboptimal. Achieving greater rates of 
blood pressure control in patients will reduce cardiovascular 
morbidity and mortality. This goal has many inherent chal-
lenges but some of these can be overcome by raising aware-
ness of the impact of hypertension, using effective therapies 
either as monotherapy or in combination as required, and 
through treatment approaches that maximize adherence. All 
classes of antihypertensive agents have been shown to provide 
end-organ protection in large outcome studies. A number 
of placebo-controlled studies, including HOPE, EUROPA, 
IDNT, IRMA2, RENAAL, and TRANSCEND, support the 
hypothesis that antihypertensive agents may have beneficial 
effects beyond their blood pressure-lowering effects. A num-
ber of other studies, including AMADEO, DETAIL, LIFE, 
and ONTARGET™, which compared active agents in popu-
lations that were already receiving other antihypertensive 
therapies demonstrated effects over and above good blood 
pressure control. In agents showing equivalent cardiovascular, 
cerebrovascular, and renal protective effects, agents offering 
better tolerability and increased patient adherence may be 
advantageous for the long-term management of hypertension 
and reduction of cardiovascular morbidity. This is particularly 
relevant when considering those studies in which ARBs and 
ACEIs have shown equivalent protection in patients screened 
for ACEI intolerance, such as the ONTARGET study. Thus, 
these and other clinical studies suggest that particular classes 
of antihypertensive therapy may have beneficial effects sepa-
rate from their effects on blood pressure.
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